William Blair sets USD 51.00 target for IDEAYA Biosciences stock

Published on 10/17/2026 at 20:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

William Blair set a USD 51.00 target on October 15, 2026. IDEAYA Biosciences stock was at EUR 33.07 on October 17, 2026.

Analyst targets shape the outlook

William Blair initiated coverage with a USD 51.00 target on October 15, 2026.
The consensus target mean was USD 53.80 as of October 3, 2026.
IDEAYA Biosciences stock was last at EUR 33.07 at Lang & Schwarz on October 17, 2026 at 10:05 a.m. CEST, with a EUR 33.07 bid and EUR 33.33 ask.
IDEAYA reports second-quarter revenue of USD 8.86 million and a GAAP net loss of USD 112.45 million.

IDYA, US45166A1025, Illustration mit AI erstellt.

William Blair initiated coverage of IDEAYA Biosciences with an Outperform recommendation and a USD 51.00 price target in a report dated October 15, 2026, according to Nasdaq. Against the USD 32.85 Nasdaq close on October 16, 2026, the target stood 55.25 percent higher. IDEAYA Biosciences was last quoted at EUR 33.07 at Lang & Schwarz on October 17, 2026 at 10:05 a.m. CEST.

Consensus target reaches USD 53.80

The broader analyst picture was also higher than the latest Nasdaq close. Nasdaq reported a consensus target mean of USD 53.80 as of October 3, 2026, with a median of USD 55.08. The source listed 22 recommendations for the September 1, 2026 period, including 7 strong-buy ratings, 13 buy ratings and 2 hold ratings.

Second-quarter revenue was USD 8.86 million

IDEAYA reported USD 8.86 million in revenue for the second quarter of 2026 and a GAAP net loss of USD 112.45 million. The loss was wider than the USD 77.49 million loss reported for the year-earlier quarter, while second-quarter diluted earnings per share were negative USD 1.22, according to Markets Insider.

Market position on October 16

On Nasdaq, IDEAYA closed at USD 32.85 on October 16, 2026, down 2.95 percent from the prior close of USD 33.85. The 52-week range was USD 26.81 to USD 42.68, and volume reached 655,113 shares against an average of 784,382 shares. Its market capitalization was USD 3.2 billion and its trailing price-to-earnings ratio was negative 16.93.

Comparison with peers

IDYA (Nasdaq, USD): minus 2.95 percent, P/E negative 16.93, market capitalization USD 3.2 billion

argenx (Nasdaq, USD): minus 3.21 percent, P/E 31.35, market capitalization USD 50.7 billion

Cullinan Therapeutics (Nasdaq, USD): minus 7.64 percent, P/E negative 3.84, market capitalization USD 794.7 million

Upcoming dates and pipeline context

The next earnings date was listed as November 2, 2026 by Nasdaq. IDEAYA also scheduled its London R&D Day for November 16, 2026, according to the company's investor-relations page.

Euro quote and valuation frame

The euro quotation gives German investors a separate trading reference, while the Nasdaq close and analyst targets remain in USD. The company is developing targeted oncology therapies selected through molecular diagnostics.